Gemphire Therapeutics Overview
- Year Founded
-
2008

- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Investors
-
2
Gemphire Therapeutics General Information
Description
Developer of novel therapies designed to treat life threatening cardiovascular or metabolic and orphan diseases. The company is engaged in developing and commercializing therapies for patients with cardiometablic disorders including dyslipidemia and nash.
Contact Information
Website
www.gemphire.comCorporate Office
- 17199 North Laurel Park Drive
- Suite 401
- Livonia, MI 48152
- United States
Corporate Office
- 17199 North Laurel Park Drive
- Suite 401
- Livonia, MI 48152
- United States
Gemphire Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
7. Merger/Acquisition | 30-Dec-2019 | Completed | Generating Revenue | |||
6. Secondary Transaction - Private | Completed | Generating Revenue | ||||
5. PIPE | 04-Sep-2017 | Completed | Generating Revenue | |||
4. PIPE | 10-Mar-2017 | Completed | Generating Revenue | |||
3. IPO | 04-Aug-2016 | Completed | Generating Revenue | |||
2. Early Stage VC (Series A) | 09-Mar-2016 | $10.6M | $10.6M | Completed | Generating Revenue | |
1. Angel (individual) | Completed | Generating Revenue |
Gemphire Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A |
Gemphire Therapeutics Former Investors (11)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Amherst Fund | Venture Capital | Minority | ||
Biobrit | Venture Capital | Minority | ||
Biosciences Research and Commercialization Center | Venture Capital | Minority | ||
BlueWater Angels | Angel Group | Minority | ||
Capital Midwest Fund | Venture Capital | Minority |
Gemphire Therapeutics Acquisitions (1)
Gemphire Therapeutics’s most recent deal was a Reverse Merger with MetaVia (Biotechnology). The deal was made on 30-Jan-2020.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
MetaVia (Biotechnology) | 30-Jan-2020 | Reverse Merger | Biotechnology |
Gemphire Therapeutics FAQs
-
When was Gemphire Therapeutics founded?
Gemphire Therapeutics was founded in 2008.
-
Where is Gemphire Therapeutics headquartered?
Gemphire Therapeutics is headquartered in Livonia, MI.
-
What industry is Gemphire Therapeutics in?
Gemphire Therapeutics’s primary industry is Drug Discovery.
-
Is Gemphire Therapeutics a private or public company?
Gemphire Therapeutics is a Private company.
-
What is Gemphire Therapeutics’s current revenue?
The current revenue for Gemphire Therapeutics is
. -
How much funding has Gemphire Therapeutics raised over time?
Gemphire Therapeutics has raised $103M.
-
Who are Gemphire Therapeutics’s investors?
Amherst Fund, Biobrit, Biosciences Research and Commercialization Center, BlueWater Angels, and Capital Midwest Fund are 5 of 11 investors who have invested in Gemphire Therapeutics.
-
When was Gemphire Therapeutics acquired?
Gemphire Therapeutics was acquired on 30-Dec-2019.
-
Who acquired Gemphire Therapeutics?
Gemphire Therapeutics was acquired by MetaVia (Biotechnology).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »